Navigation Links
Dr. Andrew Scharenberg, M.D., to Serve as Chief Scientific Officer for Cellectis therapeutics
Date:7/11/2011

PARIS, July 11, 2011 /PRNewswire/ -- Cellectis therapeutics, a subsidiary of Cellectis (Alternext: ALCLS) specializing in the development of therapeutic applications in genome engineering, today announced the appointment of Dr. Andrew M. Scharenberg as Chief Scientific Officer.

Dr. Scharenberg is an attending physician in Immunology at Seattle Children's Hospital, and Professor of Pediatrics and Immunology at the University of Washington. His academic laboratory is based at Seattle Children's Research Institute, and is world renowned for its work on the development of genome engineering technologies for innovative therapeutic applications.

Dr. Scharenberg is a principal investigator and codirector of the Northwest Genome Engineering Consortium (NGEC), which is focused on new approaches for treating genetic diseases. In addition, he is a cofounder and member of the Board of Director's of Pregenen Inc., a biotechnology spin-off from the NGEC, and a strategic partner of Cellectis focused on the commercial development of novel genome engineering technologies.

"We are thrilled that Andrew Scharenberg has accepted the post of Chief Scientific Officer of our therapeutic subsidiary," stated Chief Scientific Officer of the Cellectis group Frederic Paques. "His experience and energy will push our research teams to achieve their full potential."

About Cellectis therapeutics

Founded in 2008, Cellectis therapeutics is dedicated to the development of innovative therapeutic approaches that use meganucleases to treat genetic diseases, cancers, and persistent viral infections. Its prospective treatment targets the DNA sequence that causes disease, which may be innate (genetic disease) or acquired (viral infection, cancer). Cellectis therapeutics' aim is to fulfill unmet medical needs, giving patients new hope.

About Cellectis

Cellectis improves life by applying its genome engineering expertise to a broad range of applications, including agriculture, bioresearch and human therapeutics. Cellectis is listed on the NYSE-Euronext Alternext market (code: ALCLS) in Paris.

For further information about Cellectis, visit our website at: www.cellectis.com

Follow Cellectis on twitter : http://twitter.com/cellectis

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company's objectives based on the current expectations and assumptions of the Company's management only and involve risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.


'/>"/>
SOURCE Cellectis
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Genesis Biopharma Appoints William H. Andrews Ph.D. to Board of Directors
2. Andrew P. Mandell - Mr. Diabetes(R) to Sit On ProtoKinetix Advisory Board
3. Jonathan Moreno and Andrew Light Speak About Biotechnology and Global Warming at the National Press Club
4. BioNeutral Groups CEO, Stephen Browand and Chief Scientist, Dr. Andrew Kielbania to Appear on WVOX 1460 AM In Focus Radio Show Hosted by Dr. Dan Miller
5. Veridiam Appoints Andrew Gale as Chief Executive Officer
6. Andrew Chisholm Appointed Vice President, Sales and Corporate Accounts at Accumetrics
7. Algeta Appoints Andrew Kay as President and Chief Executive Officer
8. [video] Ronald Andrews, CEO of Clarient, Inc. Discusses Agreement With University of Pennsylvania School of Medicine on WallSt.nets 3-Minute Press Show
9. Saladax Biomedical, Inc. Announces Appointment of Gregory C. Critchfield, M.D., M.S. as Chairman of the Companys Board of Directors
10. Patrick Hwu, M.D., and Mario Sznol, M.D., Join Genesis Biopharmas Scientific and Medical Advisory Board
11. BioNeutral Elects Stephen Holt, M.D., Ph.D as Vice Chairman and Independent Director of the Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... , May 26, 2016  Agriculture nutrients are ... Des Moines, Iowa is running their nitrate ... Lake Erie and coastal regions nationwide ... to preventing this widespread issue. NECi Superior ... Upper Peninsula, developed a new, easy to use ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... manufacturing company, today announced several positive developments that position the Company for the ... result of the transaction, Craig F. Kinghorn has been appointed Chairman of the ...
(Date:5/25/2016)... ... 2016 , ... Founder of the Fitzmaurice Hand Institute in ... of the hand by the National Board of Physicians and Surgeons, as of ... in his pursuit of providing the most comprehensive, effective treatment for his patients, ...
(Date:5/25/2016)... ... May 25, 2016 , ... Biohaven Pharmaceutical Holding Company Ltd. ... the company’s orphan drug designation request covering BHV-4157 for the treatment of Spinocerebellar ... FDA. , Spinocerebellar ataxia is a rare, debilitating neurodegenerative disorder that is ...
Breaking Biology Technology:
(Date:4/15/2016)... , April 15, 2016  A new partnership ... more accurate underwriting decisions in a fraction of ... competitively priced and high-value life insurance policies to ... With Force Diagnostics, rapid testing (A1C, ... data readings (blood pressure, weight, pulse, BMI, and ...
(Date:3/31/2016)...   LegacyXChange, Inc. ... LegacyXChange is excited to release its first ... be launched online site for trading 100% guaranteed authentic ... also provide potential shareholders a sense of the value ... industry that is notorious for fraud. The video is ...
(Date:3/22/2016)... 2016 According to ... for Consumer Industry by Type (Image, Motion, Pressure, ... & IT, Entertainment, Home Appliances, & Wearable ... 2022", published by MarketsandMarkets, the market for ... USD 26.76 Billion by 2022, at a ...
Breaking Biology News(10 mins):